Distribution of Sentinel Nodes in Non‐Parotid Salivary Gland Tumors—A Feasibility Study
Cancer Reports · 2026-03 · 9 (3)
DOI: 10.1002/cnr2.70510 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Reports, online erschienen am 06.03.2026. Verfasst von Marcus Jansson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Karolinska University Hospital, Stockholm, Sweden. Hauptthemen laut MEDLINE: Salivary Gland Neoplasms, Sentinel Lymph Node. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stiftelsen Acta Oto-Laryngologica, Department of Ear Nose and Throat.
Abstract (Originalsprache)
Background
Salivary gland carcinomas are rare and heterogeneous malignancies, more common in the parotid gland but also in submandibular and minor salivary glands. Surgery, often combined with radiotherapy, is the main treatment. Management of the clinically node‐negative (cN0) neck is debated, with some favoring extensive surgery and others active surveillance. The sentinel node (SN) technique may improve nodal staging and personalized surgery but is understudied in non‐parotid tumors.
Aims
This study aimed to evaluate whether the technique is applicable to assess SN distribution in these patients. Methods and Results In this prospective observational feasibility study, 40 patients with cytologically suspected benign or malignant non‐parotid salivary gland tumors were enrolled. Preoperatively, patients received an ultrasound‐guided intratumoral injection of Tc‐99m‐labeled tracer, followed by SPECT–CT imaging for SN localization. Intraoperatively, SNs were detected using a gamma probe, and sentinel lymph node biopsy (SLNB) was performed when indicated. SNs were detected in 33 of 39 (85%) patients. Bilateral distribution of SNs was seen in two of 12 patients with minor salivary gland tumors but in none with submandibular tumors ( n = 27). One patient was excluded due to a non‐salivary gland diagnosis. SLNB was performed in 16 patients with cytology indicating aggressive malignancies in which micrometastases were detected in three patients with submandibular gland tumors and in two patients with minor salivary gland tumors.
Conclusion
SN mapping was feasible in patients with non‐parotid salivary gland tumors, with a high detection rate using SPECT–CT. SN distribution was primarily ipsilateral but bilateral in two patients with minor salivary gland tumors. Identification of SN micrometastases highlights the potential of SLNB to improve staging accuracy. Our findings support further investigation of the SN technique as a diagnostic tool in the management of cN0 neck in this rare tumor group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Karolinska University Hospital, Stockholm, Sweden.
- Department of Clinical Sciences Intervention and Technology, Division of Ear Nose and Throat Diseases, Karolinska Institute, Stockholm, Sweden.
- Medical Unit Head Neck Lung and Skin Cancer, Department of Head and Neck Surgery, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Marcus Jansson, Rusana Bark, Alexandra Elliot, Lalle Hammarstedt-Nordenvall, Caroline Gahm
Förderung
- Stiftelsen Acta Oto-Laryngologica
- Department of Ear Nose and Throat
Zitieren
APA
Jansson, M., Bark, R., Elliot, A., Hammarstedt-Nordenvall, L., & Gahm, C. (2026). Distribution of Sentinel Nodes in Non‐Parotid Salivary Gland Tumors—A Feasibility Study. Cancer Reports, 9(3). https://doi.org/10.1002/cnr2.70510
Vancouver
Jansson M, Bark R, Elliot A, Hammarstedt-Nordenvall L, Gahm C. Distribution of Sentinel Nodes in Non‐Parotid Salivary Gland Tumors—A Feasibility Study. Cancer Reports. 2026;9(3). doi:10.1002/cnr2.70510
BibTeX
@article{Jansson2026,
author = {Jansson, Marcus and Bark, Rusana and Elliot, Alexandra and Hammarstedt-Nordenvall, Lalle and Gahm, Caroline},
title = {Distribution of Sentinel Nodes in Non‐Parotid Salivary Gland Tumors—A Feasibility Study},
journal = {Cancer Reports},
year = {2026},
volume = {9},
number = {3},
doi = {10.1002/cnr2.70510}
}
EUVIMED